Chuangxin Medical's Easybridge Selected for EMA Breakthrough Device Pilot, Reshaping Global Landscape of Minimally Invasive Type A Aortic Dissection Treatment

A patient arrives at the emergency room with a tearing pain radiating through their chest. The diagnosis: Stanford Type A aortic dissection — one of the most lethal cardiovascular emergencies known to medicine. Without immediate intervention, mortality climbs by roughly 1% to 2% every hour. For decades, the only answer has been open-chest surgery: cracking the sternum, putting the patient on a heart-lung machine, and cooling the body to near-freezing temperatures. Many patients — the elderly, the frail, those with severe comorbidities — simply cannot survive the procedure.

Now a Shenzhen-based company is betting that a catheter threaded through the groin can do the job instead.

In June 2026, Chuangxin Medical announced that its Easybridge™ — an endovascular reconstruction system designed specifically for Type A aortic dissection — was selected for the European Medicines Agency's Breakthrough Device Pilot program (BtX). It is among the first Chinese cardiovascular devices to earn a spot in the program, and the first from China to be recognized in the ascending aorta minimally invasive treatment space.

The selection marks a turning point. For years, Chinese medical device companies have been followers in the aortic intervention space, adapting designs pioneered in the U.S. and Europe. Easybridge™ represents something different: a product conceived from scratch for a clinical problem that open surgery still dominates.

The Anatomy Problem

Type A aortic dissection occurs when the inner layer of the aorta tears near the heart, allowing blood to surge between the vessel wall layers. The ascending aorta — the section closest to the heart — is a particularly hostile environment for any implant. It curves sharply. It pulses with every heartbeat. Three major branch vessels feeding the brain and arms emerge from the aortic arch just centimeters away from the typical tear site.

Existing stent grafts were designed for the descending aorta, where the anatomy is simpler and straighter. Simply pushing those devices upward into the ascending aorta risks blocking blood flow to the brain or failing to seal the tear.

Chuangxin Medical built Easybridge™ from the ground up around these constraints. The device uses a modular design: a covered membrane segment to seal the tear, combined with a bare braided stent segment that preserves blood flow to the three branch vessels. The goal is threefold — reconstruct the true lumen, induce thrombosis in the false lumen, and protect branch vessel perfusion.

The company also developed a proprietary steerable delivery system. Inserted through the femoral artery, it allows physicians to precisely position and release the device in the curved, confined space of the ascending aorta and arch — without cracking the chest.

What the EMA Selection Means

The EMA Breakthrough Device Pilot is not a market approval. It is an accelerated regulatory and scientific consultation pathway for devices that address unmet medical needs and could have significant public health impact. Companies selected for the program receive priority guidance from EMA on clinical development, marketing applications, and market access — potentially shortening the path to European market entry.

For Chuangxin Medical, the selection validates the clinical value and technical innovation of Easybridge™ in the eyes of one of the world's most rigorous regulatory bodies. The company plans to accelerate European and international multicenter clinical trials to build real-world safety and efficacy data.

The CRO Behind the Push

Getting a Chinese medical device through EMA's evaluation is not straightforward. Chuangxin Medical partnered with MDCE CRO, a clinical research organization specializing in overseas clinical trials and regulatory registration for Chinese pharmaceutical and device companies.

MDCE CRO — which leverages Harvard University's global medical research resources — handled the full spectrum of the submission: indication strategy, application materials, and scientific dialogue with EMA. The BtX program had no historical precedent and no reference pathway for this type of device. MDCE CRO navigated the evaluation from strategy planning through to the final scientific consultation.

The company reports having helped more than 100 medical device and biopharmaceutical projects land overseas, with an overseas clinical trial team of over 100 people and partnerships with more than 100 hospitals across the EU, North America, Australia, Southeast Asia, Japan, South Korea, the Middle East, and Africa.

The Road Ahead

"Minimally invasive treatment for Type A aortic dissection has been a focus of the international medical community," said Peng Yucheng, founder of Chuangxin Medical. "We hope Easybridge™ can truly offer a new treatment possibility for patients who cannot undergo open surgery."

The company is headquartered in Bao'an District, Shenzhen, and focuses on endovascular solutions for aortic and peripheral vascular diseases.

Deng Xiaoyu, founder of MDCE CRO, called the selection "an important breakthrough for original Chinese medical devices on the global high-end regulatory pathway."

The EMA pilot is a door, not a destination. Chuangxin Medical still needs to complete clinical trials, secure regulatory approvals, and convince surgeons trained in open repair to adopt a catheter-based approach for one of the most dangerous conditions in cardiovascular medicine.

But for the patients who cannot survive the scalpel, that door matters.